Another day, another, somewhat nastier, virus.

Adam Spencer
18 hours ago
5 min read

Bundibugyo ebola has no approved vaccines or antivirals. WHO's emergency call reflects complexity, not global pandemic risk.

(Ebola-ish, but not ebola! Created with Midjourney)

(First published on my Substack where you can get #NerdNews, marvellous maths and general geekery.)

Emergency declared, but how worried should we be?

When the World Health Organization declares a Public Health Emergency of International Concern, it sounds appropriately dramatic. At the time of writing, there have been more than 130 deaths and over 500 suspected cases across Ituri and North Kivu provinces from a rare Ebola strain that has crossed from Democratic Republic of Congo into Uganda. There are, no approved treatments available.

But step back from the headlines and the picture becomes more nuanced. This is Bundibugyo ebolavirus — not the Zaire strain that killed over 11,000 people in West Africa a decade ago. The case fatality rate is lower, the transmission patterns are understood, and classic containment measures have worked before.

The emergency declaration reflects operational complexity and resource needs, not necessarily global catastrophe in the making.

"After having consulted the DRC and Uganda … I determine that the epidemic constitutes a public health emergency of international concern." — Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

Meet Bundibugyo: Ebola's "manageable" cousin.

Bundibugyo ebolavirus was first identified during a 2007–08 outbreak in Uganda that caused 149 suspected and confirmed cases and 37 deaths. A smaller second outbreak occurred in DRC in 2012 with several dozen cases. Until now, that was the entire human experience with this particular virus.

The molecular difference matters enormously. While all ebolaviruses are filoviruses — thread-like RNA viruses that hijack human cells with devastating efficiency — Bundibugyo's surface proteins are distinct enough that Zaire-specific treatments simply don't work.

In the same way Andes hantavirus, which we featured in our last NerdNews, developed over countless generations in rodents, Bundibugyo likely co-evolved with fruit bats over millions of years.

Like Hanta, it obeyed the smart parasite principle: "don't kill your host". Instead, like all Ebola viruses, it maintains stable infections in its natural hosts without causing distress or death.

But unfortunately for us when it spills over to humans, usually through contact with infected bat droppings or bushmeat, our immune systems encounter something completely foreign.

What makes Bundibugyo so dangerous?

It is no exaggeration to say Ebola represents natural, evolutionary biological warfare at its worst.

The virus is brutally efficient at the molecular level, targeting immune cells first, essentially destroying the very systems meant to defend us against infection. It then goes after blood vessel linings throughout the body, causing widespread capillary leak. Your blood vessels literally start leaking plasma where it doesn't belong.

What follows is the horrifying paradox of Ebola disease. Simultaneous bleeding and clotting as the virus triggers both excessive coagulation and hemorrhage. Multiple organs begin failing as vascular integrity collapses.

The good news, relatively speaking, is that case fatality rates in the past two BVD outbreaks have ranged from approximately 30% to 50% — significantly lower than the worst Zaire Ebola outbreaks, which have approached 80–90% mortality, though large outbreaks have averaged closer to 50–70%.

Critical time wasted.

The current outbreak started in Mongbwalu, a high-traffic mining area in DRC's Ituri Province. The location matters. This region is a commercial hub that borders Uganda and South Sudan, with constant population movement.

Detection delays made everything worse. The technical problem was fundamental: rapid field tests used in regional facilities like Bunia are calibrated only for the Zaire strain and completely miss Bundibugyo. Early samples from late April and early May tested negative locally, even though patients were dying from what looked like Ebola.

"Because early tests looked for the wrong strain of Ebola, we got false negatives and lost weeks of response time. We are playing catch-up against a very dangerous pathogen." — Matthew Kavanagh, Georgetown University Centre for Global Health Policy & Politics.

Only when samples reached specialized reference laboratories in Kinshasa for genomic sequencing was Bundibugyo definitively identified. By then, the virus had been spreading unrecognised for weeks.

Meanwhile, this already represents the largest known outbreak of Bundibugyo virus disease, and the virus has demonstrably crossed international borders with Uganda confirming cases.

"The number of cases and deaths we are seeing in such a short timeframe, combined with the spread across several health zones and now across the border, is extremely concerning. Rapid action is critical to prevent the outbreak from escalating further." — Trish Newport, Emergency Program Manager, Doctors Without Borders.

The treatment reality check.

So for Bundibugyo we're effectively back to 1976‑era Ebola response tools. No strain‑specific vaccines or antivirals, just isolation and supportive care, albeit delivered with far better, modern systems.

There are no licensed vaccines, antivirals, or monoclonal antibody treatments for this strain; care is largely supportive. Things like fluids, electrolyte management and treating secondary infections. All while hoping the patient's immune system finds the narrow path between viral clearance and self-destruction.

The experimental pipeline offers some hope. Clinical trials for treatments against Bundibugyo virus are 'in a strong position' to be launched quickly in the affected countries. But even fast-tracked trials take months, and regulatory approval takes longer.

Can this be stopped?

Previous Bundibugyo outbreaks were contained using traditional public health measures: case isolation, contact tracing, safe burial practices, and infection prevention in healthcare settings. The virus spreads through direct contact with bodily fluids, not airborne transmission, which makes containment theoretically achievable.

"The declaration by WHO of a Public Health Emergency reflects the operational complexity of the outbreak and the need for coordinated international support, rather than indicating a high global risk to the general public, though the regional risk in affected areas is very high." — Dr Daniela Manno, London School of Hygiene & Tropical Medicine.

Not everyone shares this measured assessment. Pointing to ongoing civil unrest in the region and the Trump administration's withdrawal from WHO and cuts to international health funding, experts writing in The Atlantic warn the global response capacity has been severely weakened.

"My projection is that it will get worse before it gets better. The outbreak has already reached a point at which experts feel certain it will be very difficult to contain." — Nahid Bhadelia, Boston University Center on Emerging Infectious Diseases.

The challenges are significant: this is happening in a region with ongoing security issues, population displacement, and limited healthcare infrastructure. But the epidemiology suggests containment is possible with sustained, well-coordinated response.

The bottom line.

Bundibugyo Ebola is genuinely dangerous and requires serious international response. But WHO's emergency declaration is about mobilising resources and expertise for a complex outbreak in challenging circumstances, not signalling imminent global catastrophe.

The lack of specific medical countermeasures makes every case medically precious, but the transmission characteristics and successful containment of previous outbreaks suggest this can be controlled with classic public health tools and international coordination.

At the same time it is certainly not guaranteed. We can only hope that the emergency procedures in place hold up.